Atheeshaan Arumuham
London, ENG SE58AF, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Targets for disease modification in schizophrenia: New findings add to evidence for the involvement of the immune complement system.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 29, 2026
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms.
Journal: JAMA psychiatry
Published: December 10, 2025
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [11C]UCB-J positron emission tomography study.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: October 07, 2025
Dopamine and Mood in Psychotic Disorders: An 18F-DOPA PET Study.
Journal: JAMA psychiatry
Published: August 13, 2025
The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Journal: Lancet (London, England)
Published: February 19, 2025
Mitochondria and Cognition: An [18F]BCPP-EF Positron Emission Tomography Study of Mitochondrial Complex I Levels and Brain Activation During Task Switching.
Journal: Biological psychiatry. Cognitive neuroscience and neuroimaging
Published: September 26, 2024
Working memory processes and the histamine-3 receptor in schizophrenia: a [11C]MK-8278 PET-fMRI study.
Journal: Psychopharmacology
Published: August 25, 2024
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging study.
Journal: Translational psychiatry
Published: March 27, 2024
Immune response to vaccination in people with psychotic disorders relative to healthy controls: prospective study of SARS-CoV-2 vaccination.
Journal: BJPsych open
Published: February 16, 2024
The relationship between SV2A levels, neural activity, and cognitive function in healthy humans: A [11C]UCB-J PET and fMRI study.
Journal: Imaging neuroscience (Cambridge, Mass.)
Published: February 08, 2024
Histamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-1H-MRS Study of Patients With Schizophrenia and Healthy Controls.
Journal: The international journal of neuropsychopharmacology
Published: November 20, 2023
The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia.
Journal: Journal of psychopharmacology (Oxford, England)
Published: June 17, 2023
Last Updated: 09/26/2026